Moreover, an effectiveness analysis including 62 patients with MetS and 32 patients without showed that the level of high-sensitivity C-reactive protein was significantly decreased in MetS patients during pitavastatin treatment, whereas high-molecular-weight adiponectin levels did not change. This evidence concerns the gene ADIPOQ and metabolic syndrome.